Harrow, Inc. provided revenue guidance for the first quarter and full year 2024. Beginning in the first quarter of 2024, the company expected moderate revenue growth from recently acquired FDA-approved products (the Fab Five and those acquired from Santen) and the recovery of compounding business to historical growth levels.

For the full year 2024, the company expected 2024 revenues to be over $180 million. The magnitude of revenue growth beyond $180 million will depend on many factors, including when we restore TRIESENCE inventory, accelerate IHEEZO sales, and generate new revenues from VEVYE.